SPYRE THERAPEUTICS, INC. Reimbursement from Limited Partnership Investment
SPYRE THERAPEUTICS, INC. (SYRE) reported Reimbursement from Limited Partnership Investment of $3.00 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-08.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:ReimbursementFromLimitedPartnershipInvestment · last filed 2022-03-08
- SPYRE THERAPEUTICS, INC. reimbursement from limited partnership investment for the quarter ending 2021-12-31 was $0.00.
- SPYRE THERAPEUTICS, INC. reimbursement from limited partnership investment for fiscal 2021 was $3.00M.
| Period end | Reimbursement from Limited Partnership Investment 3 month | Reimbursement from Limited Partnership Investment 9 month | Reimbursement from Limited Partnership Investment 12 month |
|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $3.00M 10-K · filed 2022-03-08 | |
| 2021-09-30 | $3.00M 10-Q · filed 2021-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |